Modality
mRNA
MOA
ALKi
Target
DLL3
Pathway
Lipid Met
OCDLGS
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
Oct 2020
→ Sep 2028
Phase 1Current
NCT04372386
2,071 pts·OCD
2020-10→2028-09·Not yet recruiting
NCT03256451
304 pts·OCD
2020-10→2027-08·Active
2,375 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-08-271.4y awayPh2 Data· OCD
2028-09-012.4y awayPh2 Data· OCD
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Not yet…
P1/2
Active
Catalysts
Ph2 Data
2027-08-27 · 1.4y away
OCD
Ph2 Data
2028-09-01 · 2.4y away
OCD
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04372386 | Phase 1/2 | OCD | Not yet recr... | 2071 | NT-proBNP |
| NCT03256451 | Phase 1/2 | OCD | Active | 304 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| AMG-7379 | Amgen | Preclinical | DLL3 |